Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoraci… (NCT06396598) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer
United States157 participantsStarted 2024-02-09
Plain-language summary
This clinical trial evaluates earlier symptom management through remote electronic symptom monitoring (such as through an app on patient's phone), and accessibility of palliative care self-referral by patients with thoracic cancer and caregivers by proxy (legal representative). Thoracic cancer occurs in the chest and often causes symptoms for patients. Patients and/or their caregivers are often unable to attend in-person clinic visits for various reasons. The most frequently reported symptom by patients at initial palliative care consultations is pain, and caregivers' most common concerns are pain management for the patient, stress reduction, and fears about patient decline. Earlier palliative care referral can help control these symptoms before they worsen, providing a better quality of life for patients and caregivers. improve physical and emotional functioning for patients and caregivers in cancer care. This study may help researchers learn how an electronic symptom monitoring program may provide an earlier and more accessible way for patients with thoracic cancer to receive palliative care.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* PATIENTS: Age ≥ 18 years
* PATIENTS: Diagnosed with any stage (1-4) or type (non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic carcinoma) of thoracic malignancy
* PATIENTS: ≥ 2 visits at the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic
* PATIENTS: Study enrollment within 12 weeks of initial Thoracic Medical Oncology appointment
* PATIENTS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
* PATIENTS: Ability to read and understand English
* PATIENTS: Access to a device with email or text messaging capability
* CAREGIVERS: Age ≥ 18 years
* CAREGIVERS: Identified by patient participant as primary caregiver
* CAREGIVERS: Corresponding patient participant has consented to participate in the study
* CAREGIVERS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
* CAREGIVERS: Ability to read and understand English
* CAREGIVERS: Access to a device with email or text messaging capability
Exclusion Criteria:
* PATIENTS: Patients who have been previously referred to ambulatory palliative care are excluded from participation
* PATIENTS: Prisoners are excluded from participation
* PATIENTS: Pregnant patients are excluded from participation
* PATIENTS: Patients who lack capacity for medical decision-making as determined by their primary oncologist…
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Frequency of symptom logging
Timeframe: At 6 months after enrollment
2
Proportion of patients enrolled (Feasibility)
Timeframe: At enrollment and 3 months
3
Symptom scores and Palliative Referral Association
Timeframe: At enrollment and 3 months and 6 months
4
Patient and Caregiver Symptom Reporting Congruency
Timeframe: At enrollment and 3 months and 6 months
Trial details
NCT IDNCT06396598
SponsorOhio State University Comprehensive Cancer Center